<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02523547</url>
  </required_header>
  <id_info>
    <org_study_id>HM-CAV-401</org_study_id>
    <nct_id>NCT02523547</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude</brief_title>
  <official_title>PhaseIVstudy to Evaluate the Non-inferiority of Cavir速Tab. in Terms of Hepatitis B Virus(HBV)DNA Undetectability Comparing Baraclude速 Tab. in Hepatitis B e Antigen(HBeAg)(+) Chronic Hepatitis B Patients Treated With Long-term Baraclude速 Tab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-labeled, Prospective, Randomized, Multi-center, Interventional, Phase IV study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the non-inferiority and safety in terms of HBV DNA&#xD;
      undetectability comparing Baraclude Tab. in HBeAg(+) chronic hepatitis B patients treated&#xD;
      with long-term Baraclude Tab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients with maintenance of HBV DNA undetectability</measure>
    <time_frame>48weeks</time_frame>
    <description>analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with HBeAg seroconversion</measure>
    <time_frame>at week 12, 24, 36 and 48 of treatment</time_frame>
    <description>analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with HBeAg seroclearance</measure>
    <time_frame>at week 12, 24, 36 and 48 of treatment</time_frame>
    <description>analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion with HBsAg seroclearance</measure>
    <time_frame>at week 48 of treatment</time_frame>
    <description>analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion with HBeAg seroconversion and HBsAb positive</measure>
    <time_frame>at week 48 of treatment</time_frame>
    <description>analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum HBV DNA levels</measure>
    <time_frame>at week 48 of treatment</time_frame>
    <description>analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in HBsAg titer</measure>
    <time_frame>at week 48 of treatment</time_frame>
    <description>analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ALanine amino Transferase (ALT)</measure>
    <time_frame>at week 48 of treatment</time_frame>
    <description>analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with virologic breakthrough</measure>
    <time_frame>at week 48 of treatment</time_frame>
    <description>virologic breakthrough is defined as the increase in serum HBV DNA (&gt;60IU/ml) as determined by at least 2 consecutive measurements of at least 3 month apart, during continued treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in EuroQoL Five Dimensions Questionnaire-3L(EQ-5D-3L)</measure>
    <time_frame>at week 48 of treatment</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Cavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>entecavir/0.5mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baraclude</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>entecavir/0.5mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cavir</intervention_name>
    <description>0.5mg/day</description>
    <arm_group_label>Cavir</arm_group_label>
    <other_name>entecavir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baraclude</intervention_name>
    <description>0.5mg/day</description>
    <arm_group_label>Baraclude</arm_group_label>
    <other_name>entecavir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients (over the19 years of age) currently taking Baraclude速 monotherapy for chronic&#xD;
             HBV infection for at least 24 month with &lt; HBV DNA 60 IU/mL level, HBeAg positive and&#xD;
             HBeAb negative status at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients are diagnosed Hepatitis cancer and hepatocellular carcinoma (HCC)&#xD;
&#xD;
          -  Patient has concomitant other chronic viral infection (HAV/Hepatitis C Virus&#xD;
             (HCV)/Hepatitis D Virus(HDV)/HIV)&#xD;
&#xD;
          -  Patient had documented resistance mutations at any time before or at screening&#xD;
&#xD;
          -  Patient has clinically confirmed alcoholism, autoimmune hepatitis, malignancy with&#xD;
             hepatic involvement, hemochromatosis, alpha-1 antitrypsin deficiency and Wilson's&#xD;
             Disease.&#xD;
&#xD;
          -  Patient has received antiviral agent including interferon other than Baraclude within&#xD;
             24 months before screening for this study.&#xD;
&#xD;
          -  Patient has received immunosuppressive agent within 24 weeks before screening or&#xD;
             corticosteroids for 4 weeks.&#xD;
&#xD;
          -  Clinical signs as indicated by any one of the following: Ccr(Cockroft-Gault) &lt;&#xD;
             50ml/min, Total bilirubin &gt; 3.0 mg/dl, Albumin &lt; 2.7 g/dl, Prothrombin time &gt; INR 2.3&#xD;
&#xD;
          -  Patient is pregnant or breastfeeding or willing to be pregnant&#xD;
&#xD;
          -  Patient has malignancy except for thyroid cancer and Borderline malignancy.a history&#xD;
             of treated malignancy is allowable if the patient's malignancy has been in complete&#xD;
             remission, off chemotherapy and without additional surgical intervention, during the&#xD;
             preceding five years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hanmi Pharmaceutical</last_name>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EunSol Kim</last_name>
    <phone>+82-2-410-8747</phone>
    <email>snow-white@hanmi.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>15 Sites</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MoonHwa Park, MD</last_name>
      <phone>8224109190</phone>
      <email>moonwha.park@hanmi.co.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>July 26, 2015</study_first_submitted>
  <study_first_submitted_qc>August 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2015</study_first_posted>
  <last_update_submitted>August 13, 2015</last_update_submitted>
  <last_update_submitted_qc>August 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>entecavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

